CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Cytel

Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel`s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are channeled through our locations in North America, Europe, the United Kingdom, and Asia. Together, we enable our clients to deliver the therapies that propel humanity forward.

Stanbio Laboratory

Stanbio Laboratory is committed to manufacture and market a complete line of high quality clinical diagnostic products with an unmatched level of service and support. We provide an excellent working environment in which we develop and refine our

Saluda Medical

Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed to maintain individualized, consistent therapy by precisely controlling spinal cord activation through real-time customization of waveforms on every evoked compound action potential (ECAP) at the same rate as the stimulation frequency (At stimulation frequency of 40 Hz, 40 adjustments are made each second, 3`5 million adjustments per day, and 1`2 billion adjustments per year)`

Immune-Onc Therapeutics

Immune-Onc Therapeutics, Inc. is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients.